Is Ultragenyx Pharmaceutical Inc. (RARE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.8% / 30% | 33.1% / 30% | 7.7% / 30% | 3.71% / 5% | ✗ NOT HALAL |
| DJIM | 1.8% / 33% | 33.1% / 33% | 7.7% / 33% | 3.71% / 5% | ✗ NOT HALAL |
| MSCI | 2.3% / 33% | 44.4% / 33% | 10.3% / 33% | 3.71% / 5% | ✗ NOT HALAL |
| S&P | 1.8% / 33% | 33.1% / 33% | 7.7% / 33% | 3.71% / 5% | ✗ NOT HALAL |
| FTSE | 2.3% / 33% | 44.4% / 33% | 10.3% / 50% | 3.71% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -27.6% | |
| Operating Margin | -54.7% | |
| Net Margin | -85.4% | |
| Return on Equity (ROE) | -608.5% | |
| Return on Assets (ROA) | -22.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$466M |
| Free Cash Flow | -$487M |
| Total Debt | $36M |
| Current Ratio | 2.5 |
| Total Assets | $1.5B |
Price & Trading
| Last Close | $20.00 |
| 50-Day MA | $22.43 |
| 200-Day MA | $29.21 |
| Avg Volume | 2.9M |
| Beta | 0.2 |
|
52-Week Range
$18.29
| |
About Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Ultragenyx Pharmaceutical Inc. (RARE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Ultragenyx Pharmaceutical Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Ultragenyx Pharmaceutical Inc.'s debt ratio?
Ultragenyx Pharmaceutical Inc.'s debt ratio is 1.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.3%.
What are Ultragenyx Pharmaceutical Inc.'s key financial metrics?
Ultragenyx Pharmaceutical Inc. has a market capitalization of $1.9B, and revenue of $673M. The company maintains a gross margin of -27.6% and a net margin of -85.4%. Return on equity stands at -608.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.